share_log

藥明康德：海外監管公告

WUXI APPTEC: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

Hong Kong Stock Exchange ·  Apr 29 21:23
Summary by Futu AI
無錫藥明康德於2024年4月29日發布公告，宣布將實施H股獎勵及信託計劃。該計劃旨在通過與公司股權相關的獎勵機會，吸引、激勵及保留技術精湛與經驗豐富的人才，並與股東利益達成一致。計劃將由香港中央證券信托有限公司作為受託人，使用不超過20億港元的資金透過市場內交易購買H股股票。計劃的授予條件包括公司2024年實現的營業收入達到人民幣383億元或以上。若達成基本授予條件，將利用計劃上限的一半向選定參與者授予獎勵；若同時達成基本授予條件及附加授予條件，則可利用整個計劃上限授予獎勵。該計劃的存續期限為自采納日期起至采納日期10周年前一個營業日止。公告中亦提及了計劃的管理、選定參與者的選擇、獎勵的归属及轉讓、計劃變更和終止等詳細規則。
無錫藥明康德於2024年4月29日發布公告，宣布將實施H股獎勵及信託計劃。該計劃旨在通過與公司股權相關的獎勵機會，吸引、激勵及保留技術精湛與經驗豐富的人才，並與股東利益達成一致。計劃將由香港中央證券信托有限公司作為受託人，使用不超過20億港元的資金透過市場內交易購買H股股票。計劃的授予條件包括公司2024年實現的營業收入達到人民幣383億元或以上。若達成基本授予條件，將利用計劃上限的一半向選定參與者授予獎勵；若同時達成基本授予條件及附加授予條件，則可利用整個計劃上限授予獎勵。該計劃的存續期限為自采納日期起至采納日期10周年前一個營業日止。公告中亦提及了計劃的管理、選定參與者的選擇、獎勵的归属及轉讓、計劃變更和終止等詳細規則。
Wuxi Pharmaceutical Ming Kand announced on 29 April 2024 that it will implement the H Share Award and Trust Scheme. The program aims to attract, motivate and retain technically skilled and experienced talent, aligned with shareholders' interests through bonus opportunities related to the company's equity. The scheme will be held by the Hong Kong Central Securities Trust Limited, as trustee, to purchase H-shares through in-market transactions using no more than HK$20 billion of capital. The award conditions for the program include the company's realized sales revenue of RMB383 billion or more in 2024. If the basic award conditions are met, rewards will be awarded to selected participants using half of the program cap; if the basic award conditions and additional...Show More
Wuxi Pharmaceutical Ming Kand announced on 29 April 2024 that it will implement the H Share Award and Trust Scheme. The program aims to attract, motivate and retain technically skilled and experienced talent, aligned with shareholders' interests through bonus opportunities related to the company's equity. The scheme will be held by the Hong Kong Central Securities Trust Limited, as trustee, to purchase H-shares through in-market transactions using no more than HK$20 billion of capital. The award conditions for the program include the company's realized sales revenue of RMB383 billion or more in 2024. If the basic award conditions are met, rewards will be awarded to selected participants using half of the program cap; if the basic award conditions and additional award conditions are met, the award cap can be used for the entire program. The period of validity of the scheme shall be from the date of receipt until the end of the business on the 10th anniversary of the date of receipt. The announcement also mentions detailed rules for the administration of the scheme, the selection of selected participants, the subordination and transfer of awards, changes and terminations of plans.

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.